Textbook outcome in cancer surgery and its prognostic value: a systematic review and meta-analysis.

Eur J Cancer PrevApr 29, 2026 (epub)
Clinical ResearchOncology (Medical)General Surgery

Yifan Zhang, Binghao Wang, Weihang Gao et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the prognostic value of textbook outcomes in cancer surgery across 63 cohort studies involving 393,073 patients. It found that patients not achieving textbook outcomes had significantly worse overall survival (HR = 1.51), disease-free survival (HR = 1.65), and recurrence-free survival (HR = 1.35).

Key findings

  • Patients not achieving textbook outcomes had worse overall survival (HR = 1.51, 95% CI: 1.44-1.58, P < 0.001).
  • Worse disease-free survival was observed in patients not achieving textbook outcomes (HR = 1.65, 95% CI: 1.46-1.87, P < 0.001).
  • Recurrence-free survival was also poorer for those not achieving textbook outcomes (HR = 1.35, 95% CI: 1.28-1.42, P < 0.001).
  • Prognostic value of textbook outcomes varied by cancer type, with significant findings for colorectal, esophageal, and liver cancers.

Why it matters

Understanding the prognostic implications of textbook outcomes can help clinicians assess surgical quality and predict patient survival across various cancer types, potentially guiding treatment decisions and follow-up strategies.

Source

PubMed · PMID 42053092

Published in Eur J Cancer Prev. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.